A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels

Inclusion Criteria:

Parts A and B:

• Participants with plasminogen level (concentration) within normal range at theScreening Visit.

• All females must have a negative pregnancy test at the Screening Visit and onadmission to the Clinical Unit.

• Females of non-childbearing potential must be confirmed at the Screening Visit.

• Sexually active fertile male participants with partners of childbearing potentialmust adhere to the study specific contraception methods from the time of firstadministration of study intervention until 3 months after the study Follow-up Visit.

• Have a body mass index (BMI) between 18 and 35 kg/m2 inclusive.

• For Japanese and Chinese participants (Parts A and B):

1. A Japanese participant is defined as having both parents and 4 grandparents whoare ethnically Japanese. This includes second and third generation Japanesewhose parents or grandparents are living in a country other than Japan.

2. A Chinese participant is defined as having both parents and 4 grandparents whoare ethnically Chinese. This includes second and third generation Chinese whoseparents or grandparents are living in a country other than China.Only Part B:

• For Part B (Global MAD Cohorts), at the Screening Visit participants must haveelevated Lp(a) ≥ 30 mg/dL.

Exclusion Criteria:

Parts A and B:

• History of any clinically important disease or disorder.

• History or presence of gastrointestinal, hepatic, or renal disease or any othercondition known to interfere with absorption, distribution, metabolism, or excretionof drugs.

• Any clinically important illness, medical/surgical procedure, or trauma within 4weeks of the first administration of study intervention.

• Participants with known bleeding or coagulation disorders.

• Participants who have an elevated high-sensitivity C-reactive protein (> 3 mg/L) orhave a prothrombin time/international normalized ratio (PT/INR) or activated partialthromboplastin time (aPTT) > 1.25 times × upper limit normal (ULN).

• Any clinically important abnormalities in hematology, coagulation, clinicalchemistry, urinalysis, abnormal vital signs or abnormal laboratory values.

• Any positive result on Screening for serum hepatitis B surface antigen (HBsAg),hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) or human immunodeficiencyvirus (HIV).

• Any clinically important abnormalities in rhythm, conduction, or morphology of theresting 12-lead electrocardiogram (ECG) at Screening.

• Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeksprior to the first administration of study intervention.